Durable responses to cancer immunotherapy remain restricted to a subset of patients, highlighting persistent gaps in understanding immune failure mechanisms. Dendritic cells (DCs) serve as the critical bridge between antigen recognition and adaptive immune activation, yet conventional molecular models centered on discrete components fail to fully explain heterogeneous therapeutic outcomes. This integrative mechanistic synthesis proposes that DC-mediated antitumor immunity is governed by higher-order structural determinants, including membrane microdomain organization, spatial compartmentalization of signaling, and temporal integration of antigenic and co-stimulatory cues. These features determine whether antigen presentation leads to effective T-cell priming or dysfunctional states such as exhaustion or anergy within the tumor microenvironment. By reanalyzing our validated 2025 experimental pipeline alongside high-impact contextual literature, we identify emergent properties of immune competence that transcend linear molecular interactions. The resulting framework distinguishes structurally mediated failure modes from classical resistance paradigms, providing a coherent non-reductionist explanation for variability in immunotherapy efficacy. Membrane raft repair is positioned as a key promising structural condition for effective immune integration, with direct relevance to translational and regulatory contexts involving non-pharmacodynamic platforms and New Approach Methodologies (NAM)-aligned evaluation strategies. This work proposes an integrative mechanistic framework to guide future hypothesis-driven studies and clinical advancement of DC-based approaches.
Gutiérrez-Sandoval et al. (Sat,) studied this question.